Biogen Idec Planning Phase III Studies For Heart Failure Candidate Adentri
This article was originally published in The Pink Sheet Daily
Executive Summary
A1 adenosine receptor antagonist showed promise in Phase II as an addition to standard therapy for increasing sodium excretion, protecting renal function, according to JACC study.